ASCO Annual Meeting: Gynecologic Cancer | Conference

ERBB2/ERBB3+ Uterine Cancer Shows Disease Control With Combination of Pertuzumab and Trastuzumab
June 07, 2021

Clinical activity of the combination of pertuzumab and trastuzumab in seen in patients with ERBB2/ERBB3 overexpressing uterine cancers.

Advanced Cervical Cancer Shows No Survival Benefit With Adjuvant Chemotherapy
June 04, 2021

Awaited outcomes of the phase 3 OUTBACK trial presented at the 2021 ASCO Annual Meeting do not indicate benefit of adjuvant chemotherapy for patients with cervical cancer.

Molecular-Based Classification for Endometrial Cancer Could Help Predict Survival
June 23, 2016

Researchers were able to molecularly classify endometrial cancers with distinct survival differences using a new classification tool called ProMisE that uses clinically applicable methods.

Cisplatin/Paclitaxel Plus RT Offers Good Results in Advanced Cervical Cancer
June 22, 2016

A concurrent chemotherapy and radiotherapy regimen with cisplatin and paclitaxel yielded a good response rate and strong long-term survival outcomes in patients with locally advanced or recurrent cervical cancer.

T Cell Diversity in Tumor May Influence Ovarian Cancer Outcomes
June 17, 2016

In this video Dr. Odunsi discusses a new study that found that higher T-cell diversity in ovarian cancer is associated with poor overall survival.

AXAL Immunotherapy Well-Tolerated in Recurrent Metastatic Cervical Cancer
June 16, 2016

A live attenuated bioengineered bacteria-vectored vaccine immunotherapy is well tolerated and appears to be associated with promising overall survival among women with persistent/recurrent metastatic cervical cancer.

IP Carboplatin/IV Paclitaxel Promising in Ovarian, Peritoneal Cancer
June 09, 2016

Despite hematologic toxicities and port-related adverse events, IP carboplatin plus IV dose-dense paclitaxel appears to be effective in patients with suboptimally debulked epithelial ovarian or primary peritoneal carcinoma.

Pembrolizumab Promising in PD-L1–Positive Squamous Cervical Cancer
June 08, 2016

Pembrolizumab is well-tolerated and shows promising antitumor activity and early survival rates among patients with PD-L1–positive cervical squamous cell cancer, according to preliminary results of the KEYNOTE-028 trial.

Extending Platinum-Free Interval Might Reduce Survival in Recurrent Ovarian Cancer
June 08, 2016

Extending platinum-free interval with pegylated liposomal doxorubicin, topotecan, or gemcitabine does not improve overall survival among patients with recurrent ovarian cancer.

Baseline QoL Can Predict Survival in Platinum-Resistant Ovarian Cancer
June 08, 2016

Baseline quality of life measures predict early cessation of chemotherapy and overall survival in women with platinum-resistant/refractory, recurrent ovarian cancer.